Craig is recognised for providing pragmatic, commercially focused advice to clients in the biotechnological, pharmaceutical, chemical and MedTech sectors. As well as patent drafting and prosecution, Craig advises on the development of company-wide IP strategies, funding/acquisition due-diligence, and aggressive/defensive strategies in relation to third-party IP.
Having worked closely with multi-national corporations, Craig understands the challenges associated with efficiently prosecuting large multi-national patent portfolios, whilst keeping them relevant to the business. He values this experience as it helps him to provide expert guidance to SMEs as they grow or prepare for acquisition.
Whilst part of Craig’s focus is ensuring that technical aspects of each invention is accurately captured in a patent, he understands that the value of IP can only be fully realised after understanding the commercial goals of a business, and how IP can best be exploited to help underpin those goals. It is therefore important for him to understand more generally his client’s business; enabling him to provide them with a more broad-ranging, effective and valuable set of solutions. Industry sectors for which Craig has considerable knowledge of include those concerned with the microbiome, food, formulations, anti-infectives, diagnostics and MedTech.
Craig has a proven track record of providing successful outcomes for clients, both in a wide-range of legal proceedings (including opposition, entitlement, and USPTO interviews) and in successful IP-license/assignment deals involving patents that he both drafted and prosecuted to grant. He has co-written an amicus curiae (filed with the US Supreme Court for Sequenom v Ariosa), and has assisted many clients to successfully obtain investment, including listing on AIM.
Physiology and Pharmacology
Management of Intellectual Property
“Craig Thomson, who is well versed in all things biotechnological and pharmaceutical, particularly therapeutic and diagnostic inventions. He has a “phenomenal ability to quickly grasp the key concepts in an invention and tease out the most inventive aspects so as to file the strongest possible patents. He is always on hand to guide patent strategy and has incredible patience when explaining the intricacies of the prosecution process. He is also ridiculously good fun to work with!” “He takes a practical, business-oriented approach, focusing on what will drive value in the European market in a way that enables informed decision making. In view of technological convergence, his technical versatility is invaluable.””
“Taking the reins on this initiative is Craig Thomson, an experienced handler of biotech, pharmaceutical, chemical and medical innovations. Thomson is a seasoned prosecutor and serves up trenchant advice on IP strategy in connection with technology-driven deals and enforcement issues; the broad ambit of his practice has helped him develop a refined commercial sense.”
March 24th 2021
March 3rd 2021
January 27th 2021
January 14th 2021
October 15th 2020
October 15th 2020
September 8th 2020
September 1st 2020
July 8th 2020
April 24th 2020
September 26th 2019
June 3rd 2019
Craig provides the annual lecture, “Capturing, Protecting and Exploiting Intellectual Property in Business”, on the Masters Course for “Management of Innovation and Creativity” at Glasgow Caledonian University.
As IP lead, Craig is part of the Microbiome Innovation Network, part of the KTN, whos aims are to accelerate the commercialisation of microbiome-based products and services in the UK and create a vibrant community by connecting industry and academia. Craig also wrote the IP section for the Networks Roadmap document for the industry (https://ktn-uk.org/agrifood/microbiome/).
Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …Read article
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
HGF in Europe and Knobbe Martens in the US are holding a joint webinar on 9th June. In this webinar we will explore considerations for implementing an effective strategy to …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.